These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 38854817)

  • 1. Prolonged Complete Remission Using Tislelizumab for Hepatocellular Carcinoma After Adjuvant Chemotherapy Failure: A Case Report.
    Zhu X; Dong S; Tang J; Xie R; Wu H; Guan J; Hu S
    J Hepatocell Carcinoma; 2024; 11():1005-1013. PubMed ID: 38854817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Case Report: Complete response after tislelizumab treatment in a hepatocellular carcinoma patient with abdominal lymph node metastasis.
    Deng H; Chen B; Peng D; He J; Zhao W; Chen T; Xie Z; Pang F
    Front Immunol; 2023; 14():1163656. PubMed ID: 37180122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatic arterial infusion chemotherapy, lenvatinib plus programmed cell death protein-1 inhibitors: A promising treatment approach for high-burden hepatocellular carcinoma.
    Fu S; Xu Y; Mao Y; He M; Chen Z; Huang S; Li D; Lv Y; Wu J
    Cancer Med; 2024 May; 13(9):e7105. PubMed ID: 38686567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors for advanced hepatocellular carcinoma with macrovascular invasion.
    Zhang Y; Zhang H; Xu H; Wang Y; Feng L; Yi F
    World J Surg Oncol; 2024 May; 22(1):122. PubMed ID: 38711095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complete remission in a patient with metastatic gastric cancer receiving tislelizumab combined with chemotherapy: a case report.
    Zhu Z; Dai PL; Han S; Qiu E; Wang Y; Li Z
    Front Oncol; 2023; 13():1147636. PubMed ID: 37234987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tyrosine kinase inhibitors, immune checkpoint inhibitors combined with hepatic arterial infusion of oxaliplatin and raltitrexed versus oxaliplatin, 5-fluorouracil and leucovorin for intermediate and advanced hepatocellular carcinoma: A retrospective study.
    Zang M; Hu X; Yuan G; Li R; Li W; Pang H; Li Q; Chen J
    Int Immunopharmacol; 2023 Dec; 125(Pt A):111019. PubMed ID: 37879230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study.
    Xu J; Kato K; Raymond E; Hubner RA; Shu Y; Pan Y; Park SR; Ping L; Jiang Y; Zhang J; Wu X; Yao Y; Shen L; Kojima T; Gotovkin E; Ishihara R; Wyrwicz L; Van Cutsem E; Jimenez-Fonseca P; Lin CY; Wang L; Shi J; Li L; Yoon HH
    Lancet Oncol; 2023 May; 24(5):483-495. PubMed ID: 37080222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protocol of notable-HCC: a phase Ib study of neoadjuvant tislelizumab with stereotactic body radiotherapy in patients with resectable hepatocellular carcinoma.
    Zhang B; Yue J; Shi X; Cui K; Li L; Zhang C; Sun P; Zhong J; Li Z; Zhao L
    BMJ Open; 2022 Sep; 12(9):e060955. PubMed ID: 36115673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lenvatinib, toripalimab plus hepatic arterial infusion chemotherapy in patients with high-risk advanced hepatocellular carcinoma: A biomolecular exploratory, phase II trial.
    Lai Z; He M; Bu X; Xu Y; Huang Y; Wen D; Li Q; Xu L; Zhang Y; Wei W; Chen M; Kan A; Shi M
    Eur J Cancer; 2022 Oct; 174():68-77. PubMed ID: 35981413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatic arterial infusion chemotherapy with implantable arterial access port for advanced-stage hepatocellular carcinoma: a case report.
    Jiang X; Aljbri A; Liu J; Shang L; Tian Y; Shao H
    Front Oncol; 2024; 14():1401882. PubMed ID: 38817896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Durable response of tislelizumab plus cisplatin, nab-paclitaxel followed by concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: A case report.
    Tang H; Yang D; Luo G; He J; Yi G; Chen Z; Li H; Luo Q; Huang N; Luo H
    Medicine (Baltimore); 2023 Feb; 102(7):e32924. PubMed ID: 36800614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatic Arterial Infusion Chemotherapy Plus Lenvatinib and Tislelizumab with or Without Transhepatic Arterial Embolization for Unresectable Hepatocellular Carcinoma with Portal Vein Tumor Thrombus and High Tumor Burden: A Multicenter Retrospective Study.
    Chen S; Shi F; Wu Z; Wang L; Cai H; Ma P; Zhou Y; Mai Q; Wang F; Tang S; Zhuang W; Lai J; Chen X; Chen H; Guo W
    J Hepatocell Carcinoma; 2023; 10():1209-1222. PubMed ID: 37533600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tislelizumab Plus Chemotherapy as First-line Treatment for Advanced Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction Adenocarcinoma.
    Xu J; Bai Y; Xu N; Li E; Wang B; Wang J; Li X; Wang X; Yuan X
    Clin Cancer Res; 2020 Sep; 26(17):4542-4550. PubMed ID: 32561664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non-Small-Cell Lung Cancer: A Phase 3 Randomized Clinical Trial.
    Wang J; Lu S; Yu X; Hu Y; Sun Y; Wang Z; Zhao J; Yu Y; Hu C; Yang K; Feng G; Ying K; Zhuang W; Zhou J; Wu J; Leaw SJ; Zhang J; Lin X; Liang L; Yang N
    JAMA Oncol; 2021 May; 7(5):709-717. PubMed ID: 33792623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction therapy with hepatic arterial infusion chemotherapy enhances the efficacy of lenvatinib and pd1 inhibitors in treating hepatocellular carcinoma patients with portal vein tumor thrombosis.
    Fu Y; Peng W; Zhang W; Yang Z; Hu Z; Pang Y; Hu D; Chen J; Wang J; Zhou Z; Xu L; Chen M; Zhang Y
    J Gastroenterol; 2023 Apr; 58(4):413-424. PubMed ID: 36894804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complete response to tislelizumab in a metastatic urothelial carcinoma after surgery associated with high tumor mutational burden: a case report.
    Jin J; Yang Q; Yu Y; Chen L; Pan S
    Anticancer Drugs; 2023 Apr; 34(4):595-598. PubMed ID: 36730313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Case Report: Successful conversion and salvage resection of huge hepatocellular carcinoma with portal vein tumor thrombosis and intrahepatic metastasis via sequential hepatic arterial infusion chemotherapy, lenvatinib plus PD-1 antibody followed by simultaneous transcatheter arterial chemoembolization, and portal vein embolization.
    Luo X; Chang RZ; Kuang D; Yuan M; Li GX; Zhang B; Wang YJ; Zhang WG; Ding ZY
    Front Immunol; 2023; 14():1285296. PubMed ID: 37928536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modified Hepatic Arterial Infusion Chemotherapy Combined with Lenvatinib and Camrelizumab for Advanced HCC: Two Case Reports.
    Tian Y; Jin W; Sun H; Jin D; Kang D; Li Z; Piao L
    J Hepatocell Carcinoma; 2023; 10():1587-1593. PubMed ID: 37791067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Phase 3 Randomized Clinical Trial.
    Qin S; Kudo M; Meyer T; Bai Y; Guo Y; Meng Z; Satoh T; Marino D; Assenat E; Li S; Chen Y; Boisserie F; Abdrashitov R; Finn RS; Vogel A; Zhu AX
    JAMA Oncol; 2023 Dec; 9(12):1651-1659. PubMed ID: 37796513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Postoperative pathological complete response in a patient with PD‑L1‑negative stage IIIB lung squamous cell carcinoma following neoadjuvant tislelizumab treatment combined with chemotherapy: A case report and literature review.
    Cui G; Qu D; Bai Y; Sun X; Li Y; Yang Y
    Oncol Lett; 2023 Sep; 26(3):388. PubMed ID: 37559583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.